Many months behind rival jabs from BioNTech (Nasdaq: BNTX) and Pfizer (NYSE: PFE), Moderna (Nasdaq: MRNA) and AstraZeneca (LSE: AZN), interim Phase I/IIa data on Janssen’s offering have finally arrived.
Published in the New England Journal of Medicine, the data show the firm’s single-dose coronavirus vaccine, JNJ-78436735, provided a durable immune response and was generally well-tolerated.
Neutralizing antibodies remained stable through to at least day 71, the latest timepoint available in the ongoing study, in all participants aged 18-55 years.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze